Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The effects of DNMT3B silencing on DNA methylation and tumorigenesis in a human embryonal tumor cell line
EF 2014-15
Résumé
Embryonal tumor with multilayered rosettes (ETMR) is a rare pediatric brain tumor, mostly affecting children under the age of four. ETMRs are highly malignant with survival of less than two years after diagnosis. Better understanding of these aggressive pediatric tumors is necessary to aid in proper diagnosis and treatment.
Our group has recently identified strikingly high expression levels of a gene called DNMT3B in ETMRs. DNMT3B encodes a protein termed DNA (cytosine-5-)-methyltransferase 3 beta, responsible establishing a pattern of DNA methylation (by depositing methyl groups onto DNA) that is essential for early embryonic development. In a proposed model of ETMR tumor formation, a series of events leads to “re-awakening” of an early brain developmental pathway in which a variant of DNMT3B (variant 6), specific to early brain development, continues to be expressed at later stages in the brain and after birth.
The objective of the research proposed here is to test this model by silencing the DNMT3B gene, i.e. knocking down its expression levels, in a human ETMR cell line and observing the effects on tumor formation and DNA methylation pattern. Short interfering RNA (siRNA) molecules targeting DNMT3B will be used to achieve this. These molecules operate via a mechanism of binding to the target based on sequence complementarity and subsequent target cleavage.
Understanding the role of DNMT3B in ETMRs would not only contribute to proper diagnosis, but, if the above-mentioned model is confirmed, DNMT3B could be a potential therapeutic target.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331470
Name
Bajic Andrea
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The effects of DNMT3B silencing on DNA methylation and tumorigenesis in a human embryonal tumor cell line
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dna Methylation; Dna Methyltransferase Gene Dnmt3b; Embryonal Tumor With Multilayered Rosettes (Etmr); Knockdown/Silencing Of Gene Expression; Pediatric Brain Tumors; Rna Interference; Tumorigenesis
Abstract
Embryonal tumor with multilayered rosettes (ETMR) is a rare pediatric brain tumor, mostly affecting children under the age of four. ETMRs are highly malignant with survival of less than two years after diagnosis. Better understanding of these aggressive pediatric tumors is necessary to aid in proper diagnosis and treatment.
Our group has recently identified strikingly high expression levels of a gene called DNMT3B in ETMRs. DNMT3B encodes a protein termed DNA (cytosine-5-)-methyltransferase 3 beta, responsible establishing a pattern of DNA methylation (by depositing methyl groups onto DNA) that is essential for early embryonic development. In a proposed model of ETMR tumor formation, a series of events leads to “re-awakening” of an early brain developmental pathway in which a variant of DNMT3B (variant 6), specific to early brain development, continues to be expressed at later stages in the brain and after birth.
The objective of the research proposed here is to test this model by silencing the DNMT3B gene, i.e. knocking down its expression levels, in a human ETMR cell line and observing the effects on tumor formation and DNA methylation pattern. Short interfering RNA (siRNA) molecules targeting DNMT3B <span style="line-height: 1.5em;">will be used to achieve this. These molecules operate via a mechanism of binding to the target based on sequence complementarity and subsequent target cleavage.
Understanding the role of DNMT3B in ETMRs would not only contribute to proper diagnosis, but, if the above-mentioned model is confirmed, DNMT3B could be a potential therapeutic target.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bajic, Andrea
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~